Helen Torley - Halozyme Therapeutics President CEO, Director
| HALO Stock | USD 39.12 0.15 0.38% |
CEO
Dr. Helen I. Torley is President, Chief Executive Officer, Director of the Company. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis, Prolia, Sensipar, and Miacalcin. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. She was responsible for the development of Onyxs commercial capabilities in exUS markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at BristolMyers Squibb, including regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at SandozNovartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting postmarketing clinical studies across all therapeutic areas, including oncology. Dr. Torley serves on the board of directors of Quest Diagnostics Incorporated, a diagnostic information services company. Within the past five years, Dr. Torley served on the board of directors of Relypsa, Inc., a biopharmaceutical company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland since 2014.
| Age | 55 |
| Tenure | 10 years |
| Address | 12390 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 794 8889 |
| Web | https://halozyme.com |
Latest Insider Transactions
Torley received her Bachelor of Medicine and Bachelor of Surgery degrees from the University of Glasgow and is a Member of the Royal College of Physicians .Helen Torley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Helen Torley against Halozyme Therapeutics stock is an integral part of due diligence when investing in Halozyme Therapeutics. Helen Torley insider activity provides valuable insight into whether Halozyme Therapeutics is net buyers or sellers over its current business cycle. Note, Halozyme Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Halozyme Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Helen Torley over two months ago Disposition of 13092 shares by Helen Torley of Halozyme Therapeutics subject to Rule 16b-3 | ||
Helen Torley over six months ago Exercise or conversion by Helen Torley of 10000 shares of Halozyme Therapeutics subject to Rule 16b-3 | ||
Helen Torley over six months ago Exercise or conversion by Helen Torley of 10000 shares of Halozyme Therapeutics subject to Rule 16b-3 | ||
Helen Torley over a year ago Exercise or conversion by Helen Torley of 10000 shares of Halozyme Therapeutics subject to Rule 16b-3 |
Halozyme Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 2.2207 %, meaning that it created $2.2207 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.35. Also, Return On Capital Employed is likely to grow to 0.22. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 24th of April 2024, Fixed Asset Turnover is likely to grow to 16.71, while Non Currrent Assets Other are likely to drop about 9 M.Similar Executives
| Showing other executives | CEO Age | ||
| Alexander Hardy | Biomarin Pharmaceutical | 55 | |
| MBA Renaud | Cerevel Therapeutics Holdings | 55 | |
| Emil Kakkis | Ultragenyx | 57 | |
| MBA JD | Viridian Therapeutics | 54 | |
| Jeffrey Albers | Blueprint Medicines Corp | 46 | |
| Richard Hamilton | Cerevel Therapeutics Holdings | 51 | |
| David Schenkein | Agios Pharm | 60 | |
| Robert Blum | Cytokinetics | 60 | |
| Jan Mikkelsen | Ascendis Pharma AS | 64 | |
| MBA JD | Insmed Inc | 55 | |
| Arnon Rosenthal | Alector | 68 | |
| William Lewis | Insmed Inc | 49 | |
| Michael Morrissey | Exelixis | 63 | |
| Carole MD | Larimar Therapeutics | 65 | |
| MBChB MBA | Alnylam Pharmaceuticals | 61 | |
| Cedric Francois | Apellis Pharmaceuticals | 45 | |
| Kevin Koch | Edgewise Therapeutics | 64 | |
| Dinesh Patel | Protagonist Therapeutics | 67 | |
| John Maraganore | Alnylam Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | 2.22 | ||||
| Return On Asset | 0.12 |
Halozyme Therapeutics Leadership Team
Elected by the shareholders, the Halozyme Therapeutics' board of directors comprises two types of representatives: Halozyme Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Halozyme. The board's role is to monitor Halozyme Therapeutics' management team and ensure that shareholders' interests are well served. Halozyme Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Halozyme Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Posard, Director | ||
| Mark Esq, Senior Officer | ||
| Harry Leonhardt, Senior Vice President Chief Compliance Officer, General Counsel | ||
| Jim Mazzola, Vice President Corporate Communication & Investor Relations | ||
| Dimitrios Chondros, Senior Vice President Chief Commercial Officer | ||
| Randal Kirk, Independent Director | ||
| Mark Gergen, COO, Senior Vice President | ||
| Alison Armour, Senior Vice President - Research and Development | ||
| Gary Grote, Chief Officer | ||
| Helen Torley, President CEO, Director | ||
| Laurie Stelzer, CFO and Sr. VP | ||
| Jeffrey Henderson, Director | ||
| Kenneth Kelley, Independent Chairman of the Board | ||
| Amy Fox, Senior Resources | ||
| James Daly, Director | ||
| Athena Countouriotis, Chief Medical Officer | ||
| Todd Butler, VP CEO | ||
| Christopher Bryant, Chief Operations | ||
| Bernadette Connaughton, Director | ||
| Kristin Schwartzbauer, Head Quality | ||
| Benjamin Hickey, Chief Commercial Officer | ||
| Nicole LaBrosse, CFO Director | ||
| MD MBA, Chief Officer | ||
| Jim Daly, Director | ||
| Cortney MBA, Chief Officer | ||
| Kathryn Falberg, Independent Director | ||
| Connie Matsui, Independent Director | ||
| Al Kildani, Vice President Investor Relations & Corporate Communications | ||
| Michael LaBarre, Senior Officer | ||
| JeanPierre Bizzari, Independent Director | ||
| Steve MBBS, Chief Officer | ||
| Schond Greenway, Executive Director, Investor Relations & Strategy | ||
| MRCP B, CEO President | ||
| Tram Bui, Head Communications |
Halozyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Halozyme Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 2.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 6.14 B | ||||
| Shares Outstanding | 127.05 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 99.00 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 60.08 X |
Halozyme Therapeutics Investors Sentiment
The influence of Halozyme Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Halozyme. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Halozyme Therapeutics' public news can be used to forecast risks associated with an investment in Halozyme. The trend in average sentiment can be used to explain how an investor holding Halozyme can time the market purely based on public headlines and social activities around Halozyme Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Halozyme Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Halozyme Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Halozyme Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Halozyme Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Halozyme Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Halozyme Therapeutics' short interest history, or implied volatility extrapolated from Halozyme Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.546 | Earnings Share 2.1 | Revenue Per Share 6.286 | Quarterly Revenue Growth 0.267 | Return On Assets 0.1189 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.